Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728842 · ClinicalTrials.gov registry record
Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma
A clinical trial of Melanoma; Renal Cell Carcinoma, sponsored by Indiana University.
- Active
- Registry status
- 19
- Enrollment target
- 1
- Study location
NCT03728842 is a study of Melanoma; Renal Cell Carcinoma that is active but no longer recruiting, run by Indiana University. The registered enrollment target is 19 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03728842, a study of Melanoma; Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Indiana University.
- ACTIVE NOT RECRUITING
- Registry status
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.
Conditions Studied
Interventions
- OTHER Blood collection for laboratory studies
- OTHER Data collection from medical record
Study Locations (1)
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-01-04 |
| Est. Completion | 2027-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03728842
The ClinicalTrials.gov registry entry for NCT03728842 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma; Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Blood collection for laboratory studies is the first listed.
NCT03728842 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT03728842 about?
NCT03728842 is a clinical study titled "Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma". The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.
What is the current status of trial NCT03728842?
This trial is currently active not recruiting. The enrollment target is 19 participants. The study started on 2004-01-04. Estimated completion is 2027-03-01.
What conditions does trial NCT03728842 study?
This clinical trial studies the following conditions: Melanoma; Renal Cell Carcinoma.
What interventions are being tested in trial NCT03728842?
The interventions under investigation include: Blood collection for laboratory studies (OTHER), Data collection from medical record (OTHER).
Who is sponsoring clinical trial NCT03728842?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03728842 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.